sanofi returns TroVax rights

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) returned to Oxford BioMedica plc (LSE:OXB) rights to TroVax following a

Read the full 153 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE